PTC Therapeutics Inc
XMUN:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
XMUN:BH3
|
US |
|
A
|
Abbvie Inc
SIX:ABBV
|
US |
|
K
|
Kohls Corp
XMUN:KHP
|
US |
|
M
|
Maven Brands Inc
XMUN:TLA
|
CA |
|
Bialetti Industrie SpA
F:32B
|
IT |
|
P
|
Philip Morris International Inc
XMUN:4I1
|
US |
|
T
|
Tencent Holdings Ltd
F:NNND
|
CN |
|
Fermentalg SA
PAR:FALG
|
FR |
|
O
|
Orion Oyj
F:OFK
|
FI |
|
K
|
Koninklijke Philips NV
XBER:PHIA
|
NL |
|
S
|
Sonos Inc
F:8SO
|
US |
|
CVR Energy Inc
F:FL9
|
US |
|
C
|
CompuGroup Medical SE & Co KgaA
XHAM:COP
|
DE |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 76.63 EUR with a low forecast of 52.9 EUR and a high forecast of 111.78 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
76.63
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 76.63 EUR with a low forecast of 52.9 EUR and a high forecast of 111.78 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Operating Income over the next 8 years is -4%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 8 years is -3%.
